OTCMKTS:ATRX

Adhera Therapeutics Competitors

$0.08
-0.01 (-11.76 %)
(As of 04/12/2021 03:49 PM ET)
Add
Compare
Today's Range
$0.08
Now: $0.08
$0.08
50-Day Range
$0.09
MA: $0.10
$0.13
52-Week Range
$0.02
Now: $0.08
$0.30
Volume310,938 shs
Average Volume40,697 shs
Market Capitalization$872,325.00
P/E RatioN/A
Dividend YieldN/A
Beta1.07

Competitors

Adhera Therapeutics (OTCMKTS:ATRX) Vs. ABMC, AMBS, FWDG, AKRXQ, VGLS, and BTHE

Should you be buying ATRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Adhera Therapeutics, including American Bio Medica (ABMC), Amarantus BioScience (AMBS), FutureWorld (FWDG), Akorn (AKRXQ), VG Life Sciences (VGLS), and Boston Therapeutics (BTHE).

American Bio Medica (OTCMKTS:ABMC) and Adhera Therapeutics (OTCMKTS:ATRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Profitability

This table compares American Bio Medica and Adhera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
Adhera TherapeuticsN/AN/A-3,131.56%

Risk & Volatility

American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for American Bio Medica and Adhera Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
Adhera Therapeutics0000N/A

Valuation & Earnings

This table compares American Bio Medica and Adhera Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million1.23$-680,000.00N/AN/A
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Adhera Therapeutics.

Adhera Therapeutics (OTCMKTS:ATRX) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Adhera Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Valuation and Earnings

This table compares Adhera Therapeutics and Amarantus BioScience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Amarantus BioScience has lower revenue, but higher earnings than Adhera Therapeutics.

Analyst Ratings

This is a summary of recent recommendations for Adhera Therapeutics and Amarantus BioScience, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adhera Therapeutics0000N/A
Amarantus BioScience0000N/A

Institutional & Insider Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 28.2% of Adhera Therapeutics shares are held by company insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Adhera Therapeutics and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adhera TherapeuticsN/AN/A-3,131.56%
Amarantus BioScienceN/AN/AN/A

Summary

Adhera Therapeutics beats Amarantus BioScience on 3 of the 5 factors compared between the two stocks.

Adhera Therapeutics (OTCMKTS:ATRX) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Adhera Therapeutics and FutureWorld's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adhera TherapeuticsN/AN/A-3,131.56%
FutureWorldN/AN/AN/A

Risk and Volatility

Adhera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, FutureWorld has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Valuation & Earnings

This table compares Adhera Therapeutics and FutureWorld's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A
FutureWorldN/AN/AN/AN/AN/A

FutureWorld has lower revenue, but higher earnings than Adhera Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Adhera Therapeutics and FutureWorld, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adhera Therapeutics0000N/A
FutureWorld0000N/A

Summary

Adhera Therapeutics beats FutureWorld on 2 of the 3 factors compared between the two stocks.

Adhera Therapeutics (OTCMKTS:ATRX) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Adhera Therapeutics and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adhera TherapeuticsN/AN/A-3,131.56%
Akorn-54.01%-5.13%-0.49%

Risk and Volatility

Adhera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 28.2% of Adhera Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Akorn shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Adhera Therapeutics and Akorn's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

Adhera Therapeutics has higher earnings, but lower revenue than Akorn.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Adhera Therapeutics and Akorn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adhera Therapeutics0000N/A
Akorn0000N/A

Summary

Adhera Therapeutics beats Akorn on 6 of the 9 factors compared between the two stocks.

VG Life Sciences (OTCMKTS:VGLS) and Adhera Therapeutics (OTCMKTS:ATRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for VG Life Sciences and Adhera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VG Life Sciences0000N/A
Adhera Therapeutics0000N/A

Profitability

This table compares VG Life Sciences and Adhera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VG Life SciencesN/AN/AN/A
Adhera TherapeuticsN/AN/A-3,131.56%

Earnings and Valuation

This table compares VG Life Sciences and Adhera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VG Life SciencesN/AN/AN/AN/AN/A
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A

VG Life Sciences has higher earnings, but lower revenue than Adhera Therapeutics.

Risk & Volatility

VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Summary

VG Life Sciences beats Adhera Therapeutics on 2 of the 3 factors compared between the two stocks.

Adhera Therapeutics (OTCMKTS:ATRX) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Valuation & Earnings

This table compares Adhera Therapeutics and Boston Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adhera Therapeutics$250,000.003.49$-11,980,000.00N/AN/A
Boston Therapeutics$20,000.00111.69$-3,690,000.00N/AN/A

Boston Therapeutics has lower revenue, but higher earnings than Adhera Therapeutics.

Volatility & Risk

Adhera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500.

Profitability

This table compares Adhera Therapeutics and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adhera TherapeuticsN/AN/A-3,131.56%
Boston Therapeutics-24,627.27%N/A-3,480.61%

Analyst Ratings

This is a breakdown of current ratings and price targets for Adhera Therapeutics and Boston Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adhera Therapeutics0000N/A
Boston Therapeutics0000N/A

Summary

Adhera Therapeutics beats Boston Therapeutics on 4 of the 6 factors compared between the two stocks.


Adhera Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-2.6%$4.38 million$3.65 million0.00
AMBS
Amarantus BioScience
0.0$0.01-9.8%$4.37 millionN/A0.00Gap Down
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$3.80 millionN/A0.00
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VGLS
VG Life Sciences
0.0$0.01-0.0%$3.41 millionN/A0.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-34.3%$3.00 million$20,000.00-1.01Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04-0.0%$2.91 millionN/A-0.09
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.01-5.8%$2.21 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.50-26.0%$2.10 millionN/A0.00Gap Up
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.10-50.5%$2.08 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$34.00-0.0%$1.84 million$2 million0.00
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-2.0%$1.76 millionN/A0.00Gap Down
Cardax logo
CDXI
Cardax
0.0$2.10-0.0%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-13.7%$1.54 million$530,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-5.8%$1.30 million$8.73 million0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-15.4%$1.19 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57Upcoming Earnings
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.23-6.0%$1.12 millionN/A0.00
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.05-3.3%$1.08 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01-1.4%$1.05 millionN/A0.00
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-1.3%$996,000.00N/A0.00Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.0%$995,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00-25.0%$848,000.00N/A0.00
STLT
Spotlight Innovation
0.5$0.02-0.0%$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03-1.6%$771,000.00N/A0.00Gap Down
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.08-6.3%$454,000.00N/A0.00High Trading Volume
Gap Down
BSPM
Biostar Pharmaceuticals
0.0$0.17-12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-0.0%$295,000.00N/A0.00High Trading Volume
WDBG
Woodbrook Group
0.0$1.60-7.5%$207,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.07-3.7%$119,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
PZRXQ
PhaseRx
0.2$0.03-63.9%$108,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-0.0%$9,000.00$110,000.000.00Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.05-25.3%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08-20.1%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-158.7%$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.02-0.0%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01-0.0%$0.00N/A0.00Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.